Unbinding Kinetics of a p38 MAP Kinase Type II Inhibitor from Metadynamics Simulations 论文
2017Journal of the American Chemical Society引用 227
Melanoma and MAPK PathwaysComputational Drug Discovery MethodsCancer Mechanisms and Therapy
摘要
). Next, we developed a Markov state model that allowed identifying the rate-limiting step of the ligand unbinding process. Our calculations further show that the solvation of the ligand and that of the active site play crucial roles in the unbinding process. This study paves the way to investigations on the unbinding dynamics of more complex p38 inhibitors and other pharmacologically relevant inhibitors in general, demonstrating that metadynamics can be a powerful tool in designing new drugs with engineered binding/unbinding kinetics.